FR Doc E9-8088[Federal Register: April 9, 2009 (Volume 74,
Number 67)] [Notices] [Page 16234-16235] From the Federal
Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr09ap09-105]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to Title 21 Code of Federal Regulations 1301.34(a),
this is notice that on February 2, 2009, Lipomed, Inc., One
Broadway, Cambridge, Massachusetts 02142, made application by
renewal to the Drug Enforcement Administration (DEA) for
registration as an importer of the basic classes of controlled
substances listed in schedules I and II:
|
Drug
|
Schedule
|
|
Cathinone (1235)
|
I
|
|
Methcathinone (1237)
|
I
|
|
N-Ethylamphetamine (1475)
|
I
|
|
Fenethylline (1503)
|
I
|
|
Methaqualone (2565)
|
I
|
|
Gamma Hydroxybutyric Acid (2010)
|
I
|
|
Lysergic acid diethylamide (7315)
|
I
|
|
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348)
|
I
|
|
Marihuana (7360)
|
I
|
|
Tetrahydrocannabinols (7370)
|
I
|
|
Mescaline (7381)
|
I
|
|
3,4,5-Trimethoxyamphetamine (7390)
|
I |
|
4-Bromo-2,5-dimethoxyamphetamine (7391)
|
I
|
|
4-Bromo-2,5-dimethoxyphenethylamine (7392)
|
I
|
|
4-Methyl-2,5-dimethoxyamphetamine (7395)
|
I
|
|
2,5-Dimethoxyamphetamine (7396)
|
I
|
|
2,5-Dimethoxy-4-ethylamphetamine (7399)
|
I
|
|
3,4-Methylenedioxyamphetamine (7400)
|
I
|
|
3,4-Methylenedioxy-N-ethylamphetamine (7404)
|
I
|
|
3,4-Methylenedioxymethamphetamine (7405)
|
I
|
|
4-Methoxyamphetamine (7411)
|
I
|
|
Dimethyltryptamine (7435)
|
I
|
|
Psilocybin (7437)
|
I
|
|
Psilocyn (7438)
|
I
|
|
N-Benzylpiperazine (7493)
|
I
|
|
Acetyldihydrocodeine (9051)
|
I
|
|
Dihydromorphine (9145)
|
I
|
|
Heroin (9200)
|
I
|
|
Normorphine (9313)
|
I
|
|
Pholcodine (9314)
|
I
|
|
Tilidine (9750)
|
I
|
|
3-Methylfentanyl (9813)
|
I
|
|
Amphetamine (1100)
|
II
|
|
Methamphetamine (1105)
|
II
|
|
Methylphenidate (1724)
|
II
|
|
Amobarbital (2125)
|
II
|
|
Pentobarbital (2270)
|
II
|
|
Secobarbital (2315)
|
II
|
|
Phencyclidine (7471)
|
II
|
|
Phenylacetone (8501)
|
II
|
|
Cocaine (9041)
|
II
|
|
Codeine (9050)
|
II
|
|
Dihydrocodeine (9120)
|
II
|
|
Oxycodone (9143)
|
II
|
|
Hydromorphone (9150)
|
II
|
|
Benzoylecgonine (9180)
|
II
|
|
Ethylmorphine (9190)
|
II
|
|
Hydrocodone (9193)
|
II
|
|
Levorphanol (9220)
|
II
|
|
Meperidine (9230)
|
II
|
|
Methadone (9250)
|
II
|
|
Dextropropoxyphene, bulk (non-dosage forms) (9273)
|
II
|
|
Morphine (9300)
|
II
|
|
Thebaine (9333)
|
II
|
|
Oxymorphone (9652)
|
II
|
|
Alfentanil (9737)
|
II
|
|
Sufentanil (9740)
|
II
|
|
Fentanyl (9801)
|
II
|
The company plans to import analytical reference standards
for distribution to its customers for research and analytical
purposes.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of
controlled substances listed in schedule I or II, which fall
under the authority of section 1002(a)(2)(B) of the Act (21
U.S.C. 952(a)(2)(B)) may file comments or objections to the
issuance of the proposed registration and may, at the same time,
file a written request for a hearing on such application
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections being sent via regular or
express mail should be addressed, in quintuplicate, to the Drug
Enforcement Administration, Attention: DEA Federal Register
Representative/ODL, 8701 Morrissette Drive, Springfield, VA
22152; and must be filed no later than May 11, 2009.
This procedure is to be conducted simultaneously with and
independent of the procedures described in 21 CFR 1301.34(b),
(c), (d), (e) and (f). As noted in a previous notice published
in the Federal Register on September 23, 1975, (40 FR 43745),
all applicants for registration to import a basic class of any
controlled substances in schedule I or II are and will continue
to be required to demonstrate to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, that the requirements for such registration
pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR
1301.34(b), (c), (d), (e) and (f) are satisfied.
Dated: April 1, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement Administration.
[FR Doc. E9-8088 Filed 4-8-09; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).